Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study

Journal of Urology

Volumn 177, Issue 5, 2007, Pages 1777-1781

  Kibel, Adam S ^a   Rosenbaum, Eli ^b   Kattan, Michael W ^c   Picus, Joel ^a   Dreicer, Robert ^c   Klein, Eric A ^c   Chatta, Gurkamal S ^d   Nelson, Joel B ^d   DiPaola, Robert S ^e   Roth, Bruce J ^f   Cookson, Michael S ^f   Wilding, George ^g   Jarrard, David F ^g   Beer, Tomasz M ^h   Ryan, Christopher W ^h   Petrylak, Daniel P ⁱ   Benson, Mitchell C ⁱ   Partin, Alan W ^b   Garrett Mayer, Elizabeth ^b   Eisenberger, Mario A ^b  

^a USA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g UNIVERSITY OF WISCONSIN   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

drug therapy; mortality; prostate; prostatectomy; prostatic neoplasms

Indexed keywords

DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ALOPECIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; EPISTAXIS; ERECTILE DYSFUNCTION; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLEASON SCORE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INFECTION; INSOMNIA; LACRIMATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; STOMATITIS; TASTE DISORDER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RISK FACTORS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34147162970     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.028     Document Type: Article

References (20)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10
2. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
3. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
4. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103
5. Klotz L.H., Goldenberg S.L., Jewett M.A., Fradet Y., Nam R., Barkin J., et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170 (2003) 791
6. Catalona W.J., and Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160 (1998) 2428
7. Nilsson S., Norlen B.J., and Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 43 (2004) 316
8. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572
9. Thompson Jr. I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329
10. Tannock I.F., deWit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
11. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
12. Arriagada R., Bergman B., Dunant A., LeChevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351
13. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343
14. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687
15. Roberts W.W., Bergstralh E.J., Blute M.L., Slezak J.M., Carducci M., Han M., et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 57 (2001) 1033
16. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499
17. Wirth M.P., See W.A., McLeod D.G., Iversen P., Morris T., and Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 (2004) 1865
18. Dreicer R., Magi-Galluzzi C., Zhou M., Rothaermel J., Reuther A., Ulchaker J., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 (2004) 1138
19. Febbo P.G., Richie J.P., George D.J., Loda M., Manola J., Shankar S., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 (2005) 5233
20. Beer T.M., Pierce W.C., Lowe B.A., and Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 (2001) 1273